R&D A certificate of analysis should be evidence, not a sales do... Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.
News Hims & Hers to offer unapproved peptides to customers Telehealth firm Hims & Hers will soon start selling some unapproved peptides subject to the FDA's enforcement discretion policy announced last month.
News argenx agrees Unnatural takeover deal worth up to $1.15bn argenx has agreed its second acquisition of the year, buying macrocyclic peptide drug developer Unnatural Products for $550m upfront.
News HHS doubles down on controversial peptides plan HHS unveils an enforcement holiday to manufacture of unapproved peptides - before the FDA decides if they should be allowed in compounded medicines.
News FDA issues warning letters to five unapproved GLP-1 websites In a handful of strongly-worded warning letters, the FDA is cracking down on sales of unapproved peptides - even if they're labelled for research.
News Re-rostered FDA committee backs peptide compounding Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on compounded peptides.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.